Comparative Pharmacology
Head-to-head clinical analysis: MD 76 versus RENOVIST II.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MD 76 versus RENOVIST II.
MD-76 vs RENOVIST II
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MD-76 is a contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast between vascular structures and surrounding tissues. It distributes in the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
RENOVIST II is a radiographic contrast agent that contains diatrizoate meglumine and diatrizoate sodium. It increases the radiopacity of vascular structures and organs by attenuating X-rays due to the high atomic number of iodine atoms in the molecule.
IV: 50-100 mL per dose, administered as a bolus or infusion, not to exceed 3 mL/kg total dose.
1-2 mL/kg IV bolus, not to exceed 150 mL total; may be repeated once if necessary.
None Documented
None Documented
Terminal half-life: 1.5–2 hours; prolonged in renal impairment (up to 20 hours in anuria); clinical context: allows rapid elimination, suitable for diagnostic imaging
1.2 hours in patients with normal renal function; prolonged to 8–12 hours in severe renal impairment (CrCl <30 mL/min).
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%
Renal: 95% as unchanged drug via glomerular filtration; fecal: <5%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent